Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS IN BRAZIL RECEIVING PALBOCICLIB COMBINATIONS FOR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER IN REAL WORLD SETTINGS

The objective of this study is to describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Brazil.

Study Overview

• Status: Completed
• Conditions: Breast Cancer; Breast Carcinoma

Detailed Description

The primary objective of this real world study is to describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use.

Primary Objectives

• To describe the demographic and clinical characteristics of patients who have received palbociclib combination treatments in line with locally approved indications.
• To describe adjuvant therapies received for their treatment of early or locally advanced breast cancer (Stages 0-IIIa).
• To describe treatments received in the advanced/metastatic setting, before and after palbociclib combination use.
• To describe dosing and dose changes, interruptions, delays, and discontinuations associated with palbociclib use in clinical practice.
• To describe supportive therapies received by patients while receiving palbociclib combination treatments.

• To determine the following outcome in overall population and defined subgroups for patients who had received palbociclib combination treatment for at least 6 months:

  • Progression-free survival;
  • Objective response rate (ORR);
  • Proportion of patients alive.

Exploratory Objectives

• To evaluate progression-free survival (PFS) associated with palbociclib combination treatments after 1 and 2 years following Palbociclib combination treatment.

This study will be conducted as a retrospective medical record review of patients who have received palbociclib combination treatments as first line treatment regardless of combination. The study will comprise of a medical record review conducted in Brazil. The study design is similar to a previously conducted RWE IRIS Global study previously conducted in multiple other countries (protocol no. A5481090) .

Data collection will be online via electronic data capture using electronic case report form (eCRF). Each physician will be asked to select all the medical records of approximately 5-20 patients per site (approximate total: 300 patients) who meet the inclusion criteria and then invited to complete the eCRF from each enrolled patient. Time to complete each eCRF will be 30 minutes, approximately.

In order to allow for a sufficiently long observational window, physicians will be asked to go back to a specific point in time, the index date, and sequentially select the medical records of the next 'n' patients who meet the inclusion criteria. The 'index date' will be defined as 30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil (eg, if palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole the next day, the index date will be April 2, 2018).

The advantage to a retrospective medical record review approach over a database analysis is that of being designed specifically to collect data that fulfils the study objectives. Thus, it readily collects and informs on all key drug related clinical outcome measures of critical importance to this study, in a consistent manner, across countries if reported in a medical record. The resulting data set enables direct comparisons across markets, delivering in turn greater confidence in the reliability of conclusions drawn from the research. An additional advantage of this approach lies in the ability to obtain information that only the treating physician may be aware of, such as the reasons for treatment switches or discontinuations or more perceptive questions that rely on the physician's professional opinion.

• Study Type: Observational
• Enrollment (Actual): 121

Contacts and Locations

Study Locations

• Brazil
  • Florianópolis, Brazil, 88032-005
    • Centro Especializado de Oncologia de Florianópolis
  • Goiânia, Brazil, 74110-060
    • Instituto de Mastologia e Oncologia
  • Recife, Brazil, 50070-480
    • Instituto D'Or de Pesquisa e Ensino
  • Rio de Janeiro, Brazil, 22.250-905
    • Centro de Tratamento de Tumores Botafogo
  • Rio de Janeiro, Brazil, 22281-100
    • Instituto D´or de Pesquisa e Ensino
  • Rio de Janeiro, Brazil, 22793-080
    • Instituto de Educação, Pesquisa e Gestão em Saúde
  • São Paulo, Brazil, 01323-000
    • Hospital Paulistano - INSTITUTO DE EDUCAÇÃO, PESQUISA E GESTÃO EM SAÚDE
  • São Paulo, Brazil, 04004-030
    • Hcor - Associação Beneficente Síria
  • Estado de Bahia
    • Salvador, Estado de Bahia, Brazil, 40170-110
      • NOB - Nucleo de Oncologia da Bahia
    • Salvador, Estado de Bahia, Brazil, 41.830-492
      • Ensino E Terapia de Inovação Clínica Amo - Ética
  • Federal District
    • Brasília, Federal District, Brazil, 70200-730
      • Hospital Sirio Libanes
    • Brasília, Federal District, Brazil, 70.390-700
      • Instituto D´Or de Pesquisa E Ensino - Brasília
  • Goiás
    • Goiânia, Goiás, Brazil, 74605-070
      • Hospital Araujo Jorge
  • Minas Gerais
    • Belo Horizonte, Minas Gerais, Brazil, 30.360-680
      • Oncoclínicas Do Brasil Servicos Médicos S/A - Oncocentro

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult female patients with HR+/HER2 non-metastatic breast cancer who progressed to locally advanced (stage IIIB/C) or metastatic (stage IV) breast cancer receiving palbociclib combination regimens as per the approved indication.

Description

Inclusion Criteria:

• HR+/HER2- breast cancer diagnosis with confirmed ABC/MBC
• Received palbociclib as a first line therapy
• No prior or current enrolment in an interventional clinical trial for ABC/MBC
• Have a potential follow-up period of 6 months following the index date (30 days after first palbociclib prescription: palbociclib with fulvestrant and/or palbociclib with letrozole/aromatase inhibitor).

Exclusion Criteria:

• Patients who were enrolled to receive fulvestrant but already received previous therapies

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Breast Cancer Patients; Eligible patients including patients with a potential follow-up period of 6 months following the index date

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Demographical characteristics of patients who have received palbociclib combination treatments in line with locally approved indications	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after prescribed palbociclib + partner therapy until completion of this study in 2022.
Adjuvant treatments received for subset of patients previously diagnosed with non-metastatic breast cancer who progressed to locally advanced (stage IIIB/C) or metastatic (stage IV) breast cancer.	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe treatments received in the advanced/metastatic setting before palbociclib combination use	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe treatments received in the advanced/metastatic setting after palbociclib combination use	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe dosing associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe dose changes associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe interruptions associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe delays associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe discontinuations associated with palbociclib use in clinical practice	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Describe supportive therapies received by patients while receiving palbociclib combination treatments	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Proportion of patients who are progression free following clinical outcomes in overall population and defined subgroups for patients who had a potential follow-up of 6 months after palbociclib combination treatment initiation	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Real world Objective response rate (ORR) following clinical outcomes in overall population and defined subgroups for patients who had a potential follow-up of 6 months after palbociclib combination treatment initiation	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.
Proportion of patients alive following clinical outcomes in overall population and defined subgroups for patients who had a potential follow-up of 6 months after palbociclib combination treatment initiation	30 days after the physician first prescribed palbociclib + partner therapy following the approval of the indication in Brazil . From when palbociclib + letrozole was available Feb 1, 2018 in Brazil and the physician initiated a patient on palbociclib+ letrozole until completion of this study in 2022.	30 days after the physician first prescribed palbociclib + partner therapy until completion of this study in 2022.

Collaborators and Investigators

• Sponsor: Pfizer
• Investigators: Study Director: Pfizer CT.gov Call Center, Pfizer

Publications and helpful links

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start (Actual): May 30, 2022
• Primary Completion (Actual): May 2, 2023
• Study Completion (Actual): May 2, 2023

Study Registration Dates

• First Submitted: August 15, 2022
• First Submitted That Met QC Criteria: August 15, 2022
• First Posted (Actual): August 17, 2022

Study Record Updates

• Last Update Posted (Actual): June 2, 2026
• Last Update Submitted That Met QC Criteria: June 1, 2026
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: non-metastatic breast cancer; locally advanced (stage III) breast cancer; metastatic breast cancer (stage IV)
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms
• Other Study ID Numbers: A5481168; IRIS Brazil (Other Identifier: Alias Study Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.